Core Viewpoint - 德琪医药-B (06996) shares rose over 10% in the afternoon trading session, reflecting positive market sentiment following the company's announcement of a share buyback plan and the breakthrough designation for its drug ATG-022 [1] Group 1: Share Buyback Announcement - The board of directors approved a share buyback plan, allowing the company to repurchase shares up to a total price of 40 million HKD based on market conditions [1] - The board believes that the share buyback demonstrates confidence in the company's business outlook and will ultimately benefit the company and create value for shareholders [1] Group 2: Drug Development Update - ATG-022 has received breakthrough therapy designation from the National Medical Products Administration for treating CLDN18.2 positive, HER2 negative unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma [1] - CMB International raised its long-term and peak sales forecast for ATG-022 by nearly 30% and adjusted the company's DCF target price to 8.8 HKD, corresponding to a target market value of approximately 6 billion HKD and a peak sales revenue multiple of 2.1 times [1]
德琪医药-B午后涨超10% 拟斥最多4000万港元回购股份 ATG-022获突破性治疗药物认定